• CARsgen Therapeutics announced a top-up placement of up to 23,700,000 existing shares at HK$ 19.84 each, with UBS AG Hong Kong Branch and Macquarie Capital acting as joint placing agents.
• Deal size totals HK$ 470.21 million, with net proceeds expected at about HK$ 461.96 million.
• Placing price implies 9.49% discount to May 14 close of HK$ 21.92.
• Vendor YIJIE Biotech Holding will subscribe for an equal number of new shares at HK$ 19.84 under general mandate, maintaining its stake following issuance.
• Net proceeds earmarked mainly for R&D, with remainder for facilities and working capital including commercialization build-out.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260515-12159850), on May 15, 2026, and is solely responsible for the information contained therein.